Evidence map›Paper›PMID 41559642›Full record

ArticleJournal of nanobiotechnology2026

Biomimetic nanovesicles decorated with chemotactic and target membrane proteins for lupus nephritis treatment.

Jingjing Gan, Danqing Huang, Rui Liu, Yuanjin Zhao, Lingyun Sun

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of nanobiotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Jingjing GanDepartment of Rheumatology and Immunology, Institute of Translational Medicine, Affiliated Hospital of Medical School, Nanjing Drum Tower Hospital, Nanjing University, Nanjing, 210008, China.
Danqing HuangDepartment of Rheumatology and Immunology, Institute of Translational Medicine, Affiliated Hospital of Medical School, Nanjing Drum Tower Hospital, Nanjing University, Nanjing, 210008, China.
Rui LiuDepartment of Rheumatology and Immunology, Institute of Translational Medicine, Affiliated Hospital of Medical School, Nanjing Drum Tower Hospital, Nanjing University, Nanjing, 210008, China.
Yuanjin ZhaoDepartment of Rheumatology and Immunology, Institute of Translational Medicine, Affiliated Hospital of Medical School, Nanjing Drum Tower Hospital, Nanjing University, Nanjing, 210008, China. yjzhao@seu.edu.cn.
Lingyun SunDepartment of Rheumatology and Immunology, Institute of Translational Medicine, Affiliated Hospital of Medical School, Nanjing Drum Tower Hospital, Nanjing University, Nanjing, 210008, China. lingyunsun@nju.edu.cn.

Funding

National Key Research and Development Program of China 2020YFA0710800
6 · The paper itself

Abstract

Cell membrane-coated drug delivery systems show advantages of immune escape and bio-mimicking targeting capacity; attention in this area is focusing on further enhancing their targetability for specific cells to improve delivery efficacy and therapeutic effectiveness. Here, we report a novel biomimetic nano-delivery system featured with dual‑targeting and antioxidant capacity to combat refractory lupus nephritis (LN) and promote renal injury repair. The nanocarriers of the system were prepared by cloaking glucocorticoid methylprednisolone (MP)-loaded mesoporous dopamine nanoparticles (mPDA) with chemokine receptor 4 (CXCR4)-expressing mesenchymal stem cell membranes, which inherit chemotactic and immune escape properties. In addition, by inserting the bovine serum albumin (BSA) link onto the membrane surface, the mPDA-based biomimetic carriers (BMmPMs) demonstrate a neonatal Fc receptor (FcRn)-targeting capacity, contributing to specifical cellular delivery. Based on these features, we have demonstrated that the BMmPMs exhibited enhanced renal-specific distribution and targetability, effectively alleviating immune complex deposition-induced glomerular inflammation and damage without apparent systemic side effects in LN mouse models. Thus, we believe that the proposed functionalized cell membrane-coated nano-drug delivery system has promising implication for treating LN via dual-target immunomodulation.

Indexed as

Biomimetic MaterialsLupus NephritisMembrane ProteinsNanoparticlesAnimalsBiomimeticsDrug CarriersDrug Delivery SystemsFemaleHumansKidneyMesenchymal Stem CellsMiceReceptors, CXCR4Serum Albumin, BovineDrug CarriersMembrane ProteinsReceptors, CXCR4Serum Albumin, BovineBiomimeticDrug deliveryLupus nephritisMesenchymal stem cellNanovesicle

Identifiers

PMID41559642
PMCPMC12853968

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.